Joan Montero

Sobre mi

Publicacions destacades

• HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells

  Autors:

  Alcon, Clara; Kovatcheva, Marta; Morales-Sanchez, Paula; Lopez-Polo, Vanessa; Torres, Teresa;

  (...)

  Lu, Albert; Samitier, Josep; Enrich, Carlos; Serrano, Manuel; Montero, Joan.

  Veure llistat complet d'autors

  Referència: Cell Death And Differentiation 2025.

• Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer

  Autors:

  Martin, Fernando; Alcon, Clara; Marin, Elba; Morales-Sanchez, Paula; Manzano-Munoz, Albert;

  (...)

  Lu, Albert; Villanueva, Alberto; Reguart, Noemi; Teixido, Cristina; Montero, Joan.

  Veure llistat complet d'autors

  Referència: Cell Death & Disease 2025.

• Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy

  Autors:

  Manzano-Munoz, Albert; Yeste, Jose; Ortega, Maria A; Martin, Fernando; Lopez, Anna;

  (...)

  Castro, Sandra; Serrano, Cesar; Samitier, Josep; Ramon-Azcon, Javier; Montero, Joan.

  Veure llistat complet d'autors

  Referència: Npj Precision Oncology 2022.

• Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics

  Autors:

  Montero, Joan; Haq, Rizwan;

  Referència: Cancer Discovery 2022.

• MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia

  Autors:

  Manzano-Munoz, Albert; Alcon, Clara; Menendez, Pablo; Ramirez, Manuel; Seyfried, Felix;

  Debatin, Klaus-Michael; Meyer, Luder H; Samitier, Josep; Montero, Joan.

  Referència: Frontiers In Cell And Developmental Biology 2021.

• Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance

  Autors:

  Alcon, Clara; Manzano-Munoz, Albert; Prada, Estela; Mora, Jaume; Soriano, Aroa;

  (...)

  Gallego, Soledad; Roma, Josep; Samitier, Josep; Villanueva, Alberto; Montero, Joan.

  Veure llistat complet d'autors

  Referència: Cell Death & Disease 2020.

• A New CDK9 Inhibitor on the Block to Treat Hematologic Malignancies

  Autors:

  Alcon, Clara; Manzano-Munoz, Albert; Montero, Joan;

  Referència: Clinical Cancer Research 2020.

• Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies

  Autors:

  Montero, Joan; Gstalder, Cecile; Kim, Daniel J; Sadowicz, Dorota; Miles, Wayne;

  (...)

  Hodi, F Stephen; Yoon, Charles H; Letai, Anthony; Fisher, David E; Haq, Rizwan.

  Veure llistat complet d'autors

  Referència: Nature Communications 2019.

• Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax

  Autors:

  Montero, Joan; Stephansky, Jason; Cai, Tianyu; Griffin, Gabriel K; Cabal-Hierro, Lucia;

  (...)

  Stone, Richard M; Konopleva, Marina; Pemmaraju, Naveen; Letai, Anthony; Lane, Andrew A.

  Veure llistat complet d'autors

  Referència: Cancer Discovery 2017.

• Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

  Autors:

  Montero, Joan; Sarosiek, Kristopher A; DeAngelo, Joseph D; Maertens, Ophelia; Ryan, Jeremy;

  (...)

  Jaenne, Pasi A; Amrein, Philip C; Cichowski, Karen; Drapkin, Ronny; Letai, Anthony.

  Veure llistat complet d'autors

  Referència: Cell 2015.

Projectes destacats

• ABT-199 based therapies to treat neuroblastoma

  Investigador/a principal: Juan José Montero Boronat

  Codi: FP00019758_SA001

  Durada: 01/06/2024 - 31/05/2029

• Real-time tracking of apoptosis for precision medicine (RTAPREMED)

  Investigador/a principal: Juan José Montero Boronat

  Finançador: Ministerio de Ciencia e Innovación

  Codi: PDC2022-133583-I00

  Durada: 01/12/2022 - 30/11/2024

• Centralization of pathological diagnosis and implementation of precision medicine strategies in sarcoma.

  Investigador/a principal: Enrique de Álava

  Finançador: Asociación Española Contra el Cáncer (AECC)

  Durada: 01/11/2022 - 31/10/2025

• Eliminación selectiva de células senescentes inducidas por terapia para evitar la recaída del cáncer de pulmón.

  Investigador/a principal: Juan José Montero Boronat

  Finançador: Ministerio de Ciencia e Innovación. Universidades

  Codi: PID2021-128644OB-I00

  Durada: 01/09/2022 - 31/08/2025

• ‍Integrative analysis in dynamic resistance in non-responding relapsed pediatric acute lymphoblastic leukemia patients

  Codi: DJCLS 19R/2022

  Durada: 01/09/2022 - 31/08/2025